Connection

Payam Tabarsi to Prospective Studies

Back to Details
This is a "connection" page, showing publications Payam Tabarsi has written about Prospective Studies.
Payam Tabarsi
Connection Strength
0.127
Prospective Studies
  1. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. Int Immunopharmacol. 2020 Dec; 89(Pt B):107102.
    View in: PubMed
    Score: 0.036
  2. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. Int Immunopharmacol. 2020 Nov; 88:106869.
    View in: PubMed
    Score: 0.036
  3. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. Int Immunopharmacol. 2020 Aug; 85:106688.
    View in: PubMed
    Score: 0.036
  4. Diagnosis of COVID-19 by Serology in Admitted Patients with Negative RT-PCR Assay. Iran J Allergy Asthma Immunol. 2021 Aug 07; 20(4):394-401.
    View in: PubMed
    Score: 0.010
  5. Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial. Int Immunopharmacol. 2021 Oct; 99:108043.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.